An interventional study of ELIOS and Competitor Device in Open Angle Glaucoma, sponsored by Elios Vision, Inc.. Recruiting at 16 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Elios Vision, Inc. (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Treatment
The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.
This study's planned enrollment of 194 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Elios Vision, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
First submitted before Elios Vision, Inc. became part of Bausch Health Companies Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ELIOS
Procedure: ELIOS
Competitor Device
Procedure: Competitor Device
Following cataract surgery, surgeon will proceed to ELIOS treatment.
Following cataract surgery, surgeon will proceed to Competitor treatment.
PRIMARY EFFECTIVENESS ENDPOINTS : IOP
Mean change in post-washout diurnal IOP from baseline to 12 months.
Time frame: 12 months
SECONDARY EFFECTIVENESS ENDPOINTS : Post-washout diurnal IOP
Proportion of patients achieving 20% reduction in post-washout diurnal IOP from baseline.
Time frame: 24 months
SECONDARY EFFECTIVENESS ENDPOINTS : Number of hypotensive medications
change in number of hypotensive medications from screening to 12 months
Time frame: 12 months
SECONDARY EFFECTIVENESS ENDPOINTS : Treated IOP
Mean change in treated IOP from screening to 12 months
Time frame: 12 months
SECONDARY EFFECTIVENESS ENDPOINTS : Medications
Proportion of patients Medication free at 12 months
Time frame: 12 months
SAFETY ENDPOINTS : adverse events
Rates of ocular adverse events
Time frame: 24 months
Safety endpoints: Retinal nerve fiber layer thickness
measurement of Retinal nerve fiber layer thickness
Time frame: 12 months (with a planned extension of analysis at 24 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.
Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 48 months is above that.
Counting every sponsor, half of 170 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.